¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"hemoglobin M disease"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • parasitic disease
    1. ±â»ýÃæº´ 2. ±â»ýÃæÁúȯ
  • Parkinson¡¯s disease
    ÆÄŲ½¼º´
  • paroxysmal disease
    ¹ßÀÛ¼ºÁúȯ
  • pelvic inflammatory disease
    °ñ¹Ý¿°ÁõÁúȯ, °ñ¹Ý¿°
  • pericardial disease
    ½ÉÀ帷º´, ½É³¶Áúȯ
  • periodontal disease
    Ä¡ÁÖº´, Ä¡ÁÖÁúȯ
  • peripheral arterial disease
    ¸»Ãʵ¿¸ÆÁúȯ
  • peripheral vascular disease
    ¸»ÃÊÇ÷°üº´
  • Roussy-Levy disease
    ·ç½Ã-·¹ºñº´
  • runt disease
    ·±Æ®º´, ¼Ò¸ðº´
  • rat-bite disease
    Áã¹°¸²º´
  • Raynaud¡¯s disease
    ·¹À̳뺴
  • recessive hereditary disease
    ¿­¼ºÀ¯Àüº´
  • Refsum¡¯s disease
    ·¹ÇÁ¼ûº´
  • renal disease
    ÄáÆÏº´, ½ÅÀ庴
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • sickle cell disease
    ³´ÀûÇ÷±¸º´, °â»óÀûÇ÷±¸º´
  • sleeping disease
    ¼ö¸éº´
  • slow disease
    Áö¹ßÁúȯ
  • specific disease
    ƯÀÌÁúȯ
  • spinal disease
    ô¼öº´
  • spinocerebellar disease
    ô¼ö¼Ò³úº´
  • spirochetal disease
    ½ºÇÇ·ÎÇ쟺´
  • sterility disease
    ºÒÀÓº´
  • storage disease
    ÃàÀûº´
  • subclinical disease
    ºÒÇö¼ºº´
  • systemic disease
    Àü½Åº´
  • thoracic disease
    °¡½¿º´, ÈäºÎÁúȯ
  • tick-borne disease
    Áøµå±â¸Å°³º´
  • trophoblastic disease
    ¿µ¾ç¸·º´
  • tropical disease
    ¿­´ëº´
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • VDRL test= venereal disease research laboratory test
    ¼ºº´¿¬±¸¼Ò½ÄÅ×½ºÆ®.
  • Von Recklinghausens disease(neurofibromatosis)
    Æù·¹Å¬¸µÇÏ¿ìÁ¨º´<½Å°æ¼¶À¯Á¾Áõ>.
  • Weber Christian disease
    ¿þ¹ö-Å©¸®½º Ä£º´.
  • Weils disease
    ¿ÍÀϺ´(Ȳ´ÞÃâÇ÷¼º ·¾Å佺ÇǶóÁõ).
  • Weils disease
    ¿ÍÀϺ´(Ȳ´ÞÃâÇ÷¼º ·¾Å佺ÇǶóÁõ).
  • Weils disease
    ¿ÍÀϺ´(Ȳ´ÞÃâÇ÷¼º ·¾Å佺ÇǶóÁõ).
  • Wernicke s disease
    º£¸£´ÏÄɺ´.
  • Wernickes disease
    º£¸£´ÏÄɺ´.
  • Wilsons disease
    Àª½¼º´
  • accumulation disease
    ÃàÀûº´(õëîÝÜ»).
  • acquired cystic disease of the kidney
    ÈÄõ¼º ½Å³¶Æ÷Áúȯ
  • acquired disease
    ÈÄõ¼º Áúº´(¡­òðÜ»).
  • acquired heart disease =AHD
    ÈÄõ¼º ½ÉÁúȯ(¡­ãýòðü´).
  • acute demyelinating disease
    ±Þ¼º Å»¼öÃʼº Áúȯ(¡­÷­âÐõ¦àõòðü´).
  • acute febrile neutrophilic dermatosis ; Sweet disease
    ±Þ¼º À¯¿­ È£Áß±¸¼º ÇǺÎÁõ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • cine magulomatous disease
  • climatic disease
    ±âÈĺ´(˻̷ËÓ).
  • cold agglutinin disease
    ÇÑ·©ÀÀÁýÁúȯ(¡­ëêó¢òðü´).
  • cold hemagglutinin disease
    ÇÑ·©(Àû)Ç÷±¸ÀÀÁý¼Ò Áúȯ
  • cold hemagglutinin disease=CHD
    ÇÑ·©Ç÷±¸ÀÀÁý¼Òº´
  • collagen disease
    ±³¿ø(Áú)º´(Îïê«òõÜ»).
  • collagen disease
    ±³¿ø(Áú)º´(Îïê«òõÜ»). ÄݶóÁ¨º´(¡­Ü»)
  • collagen-vascular disease
    ±³¿ø-Ç÷°ü Áúȯ
  • comb disease
    °è°üº´.
  • combined immunodeficiency disease
    º¹ÇÕÇü¸é¿ª°áÇÌÁúȯ
  • combined immunodeficiency disease
    º¹ÇÕÇü ¸é¿ª°áÇÌÁúȯ
  • combined system disease
    º¹ÇÕ°èÅëÁúȯ.
  • combined valvular disease
    º¹ÇÕÆÇ¸·Áúȯ.
  • communicable disease
    Àü¿°º´
  • communicable disease control
    Àü¿°º´°ü¸®(ÊÙË´Ëö), Àü¿°º´¿¹¹æ.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
CCD calibration curve data; central core disease; charge-coupled device; childhood celiac disease; cleid...
CDC calculated date of confinement; cancer diagnosis center; capillary diffusion capacity; cell division...
CID cellular immunodeficiency; charge injection device; chick infective dose; combined immunodeficiency ...
CLD chloride diarrhea; chronic liver disease; chronic lung disease; congenital limb deficiency; crystal ...
CSPINE corticosteroid use, seropositive RA, peripheral joint destruction, involvement of cervical nerves, n...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
COPD Chronic Obstructive Pulmonary Disease
CRDQ Chronic Respiratory Disease Questionnaire
CRQ Chronic Respiratory Disease Questionnaire
CBD Chronic beryllium disease
CBDC Chronic bullous disease of childhood
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • vagabonds' disease
    ºÎ¶ûÀÚº´
  • valvular disease
    ÆÇ¸·º´, ÆÇ¸·º´
  • valvular disease of heart
    ½ÉÀåÆÇ¸·Áõ
  • valvular heart disease
    ÆÇ¸·¼º ½ÉÁúȯ
  • VDRL : Venereal Disease Research LaboratoryÀÇ ¾àÀÚ. ¸Åµ¶±ÕÀÇ Reagin¿¡ ´ëÇÑ Ç×ü·Î, ¸Åµ¶ÀÇ ¼±º°°Ë»ç·Î »ç¿ëµÇ¸ç ¸Åµ¶ Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀ ¿©ºÎ°¡ Ä¡·á È¿°ú ÆÇÁ¤¿¡ »ç¿ëµÈ´Ù. ¸Åµ¶ ¿Ü¿¡µµ Àü½Å¼º È«¹Ý¼º ³¶Ã¢(SLE), ·ù¸¶ÅäÀÌµå °üÀý¿° µî¿¡¼­µµ ¾ç¼ºÀ¸·Î ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
    VDRL ¸é»ó ¹ÝÀÀ
  • venereal disease control
    ¼ºº´ °ü¸®
  • viral respiratory disease
    ¹ÙÀÌ·¯½º È£Èí±â Áúȯ, ¹ÙÀÌ·¯½º¼º È£Èí±â Áúȯ
  • virus disease
    ¹ÙÀÌ·¯½º Áúȯ
    1. ¹ÙÀÌ·¯½º´Â ¼÷ÁÖ¿¡ ħÀÔÇÏ°í ¶ÇÇÑ ¼÷ÁÖ¸¦ ÀÌ¿ëÇÏ¿© Áõ½ÄÇÔÀ¸·Î½á ÁúȯÀ» ÀÏÀ¸Å²´Ù. 2. È£Èí±â, ¼ÒÈ­±â°è, Ç¥ÇÇ-»óÇÇ, Ç츣Æä½º ¹ÙÀÌ·¯½º ÁúȯÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù.
  • volkmann's disease
    ÆúÅ©¸¸ Áúȯ
    ¼±Ãµ¼º ¹ßÀÇ ±âÇüÀ¸·Î¼­ °æÁ·±Ù°ñÀÇ Å»±¸°¡ ¿øÀÎ.
  • Von Gierke's disease
    Æù ±â¿¡¸£ÄÉ º´
  • von Willebrand disease
    von Willebrand Áúȯ
  • von Willebrand's disease
    Æù ºô¸®ºê¶õÆ® º´, Æùºô·¹ºê¶õµåº´
    ¼±Ãµ¼º À¯Àü¼º ¼ÒÁú·Î, »ó¿°»öü¼º ¿ì¼º ÇüÁú·Î À¯ÀüµÇ¸ç ÃâÇ÷ ½Ã°£ÀÇ ¿¬Àå, ÀÀ°í ÀÎÀÚ 8ÀÇ °áÇÌÀ» Ư¡À¸·Î ÇÑ´Ù. ºñ ÃâÇ÷°ú °ü·ÃÀÌ ÀÖÀ¸¸ç ¿Ü»ó ȤÀº ¼ö¼ú ÈÄÀÇ ÃâÇ÷, ¿ù°æÃâÇ÷, ºÐ¸¸ ÈÄ ÃâÇ÷ µîÀÌ ÇöÀúÈ÷ Áõ°¡ÇÑ´Ù..
  • wasting disease
    ¼Ò¸ðº´
  • weber christian disease
    ¿þ¹ö-Å©¸®½ºÂùº´
  • Weber-Christian disease °áÀý¼º, ºñÈ­³ó¼º, ÇÇÇÏ Áö¹æÁ¶Á÷ÀÇ ¿°Áõ.

    Weber-Cocayne syndrome

    ¿þ¹ö ÄÚÄÉÀÎ ÁõÈıº
    ±¹ÇѼºÀÇ Ç¥ÇÇ ¼öÆ÷Áõ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
Centres for Disease Control The federal facility for disease eradication, epidemiology, and education headquartered in Atlanta, Georgia, which encompasses the Centre for Infectious Diseases, Centre for Environmental Health, Centre for Health Promotion and Education, Centre for Prevention Services, Centre for Professional Development and Training, and Centre for Occupational Safety and Health. Formerly named Centre for Disease Control (1970), Communicable Disease Centre (1946).
(05 Mar 2000)
centres for disease control and prevention See: CDC.
(12 Dec 1998)
Voltolini's disease Disease of the labyrinth, leading to deafmutism, in young children.
(05 Mar 2000)
Pel-Ebstein disease The remittent fever common in Hodgkin's disease.
Synonym: Pel-Ebstein disease.
(05 Mar 2000)
Pelizaeus-Merzbacher disease A sudanophilic leukodystrophy with a tigroid appearance of the myelin resulting from patchy demyelination. Type 1-classic, nystagmus and tremor appearing in the first few months of life, followed by slow motor development sometimes with choreoathetosis, spasticity, optic atrophy and seizures, with death in early adulthood, X-linked recessive inheritance; type 2-contralateral form with death in months to years after birth, X-linked recessive inheritance; type 3-transitional, with death in the first decade; type 4-adult form associated with involuntary movements, ataxia and hyperreflexia, but without nystagmus; type 5-variant forms. Cockayne is sometimes included as a sixth form.
Synonym: Merzbacher-Pelizaeus disease.
(05 Mar 2000)
Pellegrini's disease A calcific density in the medial collateral ligament and/or bony growth at the internal condyle of the femur.
Synonym: Pellegrini-Stieda disease.
(05 Mar 2000)
Pellegrini-Stieda disease A calcific density in the medial collateral ligament and/or bony growth at the internal condyle of the femur.
Synonym: Pellegrini-Stieda disease.
(05 Mar 2000)
glycogen storage disease <hepatology> A group of inherited metabolic disorders involving the enzymes responsible for the synthesis and degradation of glycogen. In some patients, prominent liver involvement is presented. In others, more generalised storage of glycogen occurs, sometimes with prominent cardiac involvement.
Synonym: glycogenosis
(12 Sep 2002)
glycogen storage disease type I <disease> An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycaemia due to lack of glucose production.
Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
Inheritance: autosomal recessive.
(12 Dec 1998)
glycogen storage disease type II <disease> Glycogenosis due to alpha-1,4-glucosidase (acid maltase) deficiency. It affects muscle, heart, and other organs.
(12 Dec 1998)
glycogen storage disease type III <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system).
The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type IV <disease> An autosomal recessive metabolic disorder due to a deficiency in expression of branching enzyme (alpha-1,4-glucan-6-alpha-glucosyltransferase), resulting in an accumulation of abnormal glycogen with long outer branches. Clinical features are muscle hypotonia and cirrhosis. Death from liver disease usually occurs before age 2.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type V <disease> Glycogenosis due to muscle phosphorylase deficiency. Characterised by painful cramps following sustained exercise.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VI <disease> A hepatic glycogen storage disease in which there is an apparent deficiency of hepatic phosphorylase activity. However, studies have not been able to distinguish between phosphorylase deficiency and phosphorylase kinase deficiency in patients with hepatic glycogenosis.
(12 Dec 1998)
glycogen storage disease type VII <disease> An autosomal recessive muscle glycogen storage disease in which there is deficient expression of muscle phosphofructokinase activity, resulting in increased concentrations of glucose-6-phosphate and fructose-6-phosphate and low concentrations of fructose-1,6-diphosphate in muscle tissue.
Glycogen storage in muscle is increased, perhaps due to activation of glycogen synthase by accumulated glucose-6-phosphate. It has been proposed that shunting of glucose-6-phosphate and fructose-6-phosphate into the pentose phosphate pathway may result in increased synthesis of purines and pyrimidines, causing hyperuricaemia and gout.
Erythrocytes from patients may show decreased phosphofructokinase activity and 2,3-diphosphoglycerate deficiency. Exercise intolerance is present and severe congenital muscular dystrophy has been reported.
Inheritance: autosomal recessive
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á